Research programme: fibrosis therapeutics - Galapagos

Drug Profile

Research programme: fibrosis therapeutics - Galapagos

Latest Information Update: 05 Feb 2014

Price : $50

At a glance

  • Originator Galapagos NV
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Research Fibrosis

Most Recent Events

  • 03 Feb 2014 Galapagos is conducting fibrosis research in Belgium
  • 08 Mar 2013 The alliance between Galapagos and Roche in both Chronic obstructive pulmonary disease and Fibrosis has been ended
  • 08 Mar 2013 Early research is ongoing in Belgium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top